Scaglioni, Pier Paolo

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

Kim, J., McMillan, E., Kim, H. S., Venkateswaran, N., Makkar, G., Rodriguez-Canales, J., Villalobos, P., Neggers, J. E., Mendiratta, S., Wei, S., et al. (2016) · Nature

Nuclear Structure and FunctionLung Cancer Treatments and Mutations

Cited by 202

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

Gerber, D. E., Camidge, D. R., Morgensztern, D., Cetnar, J., Kelly, R. J., Ramalingam, S. S., Spigel, D. R., Jeong, W., Scaglioni, P. P., Zhang, S., et al. (2020) · Lung Cancer

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 167

Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring K-RAS Mutations

Konstantinidou, G., Bey, E. A., Rabellino, A., Schuster, K., Maira, M. S., Gazdar, A. F., Amici, A., Boothman, D. A., & Scaglioni, P. P. (2009) · Cancer Research

PI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations

Cited by 142

RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas

Konstantinidou, G., Ramadori, G., Torti, F., Kangasniemi, K., Ramirez, R. E., Cai, Y., Behrens, C., Dellinger, M. T., Brekken, R. A., Wistuba, I. I., et al. (2013) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 114

Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer

Tang, K.-J., Constanzo, J. D., Venkateswaran, N., Melegari, M., Ilcheva, M., Morales, J. C., Skoulidis, F., Heymach, J. V., Boothman, D. A., & Scaglioni, P. P. (2016) · Clinical Cancer Research

DNA Repair MechanismsProtein Kinase Regulation and GTPase Signaling

Cited by 91